title: In Vivo Target Validation Using Biological Molecules in Drug Development.
abstract: Drug development is a resource-intensive process requiring significant financial and time investment. Preclinical target validation studies and in vivo testing of the therapeutic molecules in clinically relevant disease models can accelerate and significantly de-risk later stage clinical development. In this chapter, we will focus on (1) in vivo animal models and (2) pharmacological tools for target validation.
authors.affiliation: Bayer HealthCare, 455 Mission Bay Blvd. South, Suite 493, San Francisco, CA, 94158, USA. derek.sim@bayer.com.
authors.forename: Derek S
authors.initials: DS
authors.lastname: Sim
authors.affiliation: Bayer HealthCare, 455 Mission Bay Blvd. South, Suite 493, San Francisco, CA, 94158, USA.
authors.forename: Katalin
authors.initials: K
authors.lastname: Kauser
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D051379:Mice; D058990:Molecular Targeted Therapy
keywords: Bleeding disorders; Gene therapy; Gene-editing; Hemophilia; Monoclonal antibodies; Mouse models; Non-mammalian models; Recombinant proteins; Target validation